Announcement on Subsidiary Obtaining Notice of Approval for Drug Clinical Trials
Release time:
2021-05-20
Securities Code: 600668 Securities Abbreviation: Jianfeng Group No: pro 2021-001
Zhejiang Jianfeng Group Co., Ltd.
Announcement on Subsidiaries Obtaining Drug Clinical Trial Approval Notice
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
Important Note:
- Company's approval notice for drug clinical trials will not have a significant impact on the company's recent operating results.
- Risk Warning: Due to the particularity of drug research and development, the pre-development of drugs and the long cycle and many links of products from development, clinical trials to production are susceptible to some uncertain factors, clinical trial progress, There are many uncertainties in the results and the future product market competition situation.
1. Summary
Recently, Zhejiang Erying Pharmaceutical Co., Ltd. (hereinafter referred to as "Erying Company") and , the controlling subsidiary of Zhejiang Jianfeng Pharmaceutical Co., Ltd., the controlling subsidiary of the Company, received the Notice of Approval for Clinical Trials of Drugs approved and issued by the State Drug Administration. The relevant details are hereby announced as follows:
2. drug basic information content
drug name: acetaminophen suppository
English name: Paracetamol Suppositories
dosage form: suppository
application classification: generic drug application
specification: 75mg , 125mg
registration classification: chemical drugs category 3
applicant: Zhejiang erying drug co., ltd.
approval conclusion: "according to the the People's Republic of China drug administration law and relevant regulations, after examination, the acetaminophen suppository accepted on 2020 5 February 13 meets the relevant requirements for drug registration, it is recommended that the bioequivalence study of this product be carried out in healthy adults with a single fasting dose, and that the study of BE be exempted under different specifications to meet pharmaceutical requirements."
3. Drug Research and Development and Investment
Acetaminophen Suppository is an antipyretic analgesic developed by Erying Company. Its registered classification belongs to chemical drug 3 . Acetaminophen Suppository is indicated for fever caused by common cold or influenza in children, and is also used for relieving mild to moderate pain such as headache, arthralgia, migraine, toothache, myalgia and neuralgia. As of the date of this announcement, the accumulated research and development expenses and technical investment of the project totaled about RMB ,788.09 . Market Situation of
4. Similar Drugs
Acetaminophen Suppository was first developed by German Bene Company and listed in Germany in 1960 . In 2019 , the dosage of German acetaminophen Suppository was about 1.08 .6 billion tablets (data source: IMS ). At present, paracetamol suppositories of infant specifications have been listed in many countries in the world. At present, paracetamol suppositories of 125 mg , 150 mg , 300 mg and 600 mg have been listed in China, of which 125 mg and 150 mg are used for fever caused by common cold or influenza in children aged 1-6 , no paracetamol suppositories exist for infants and young children aged 0-1 years. Acetaminophen suppository (75 mg ) developed by Erying Company is suitable for antipyretic and analgesic treatment for infants aged 0-1 years old in China. Acetaminophen suppository (125 mg ) is suitable for infants aged 6 months to 2 years old (administered according to age and weight). Scientifically administered acetaminophen suppository will be provided for infants aged 0-2-2-116 years old. Approval Procedures to Be Performed for Listing of 5. Products
Er Ying Company will conduct clinical trials (bioequivalence studies) according to the requirements of the Notice of Approval of Drug Clinical Trials. After the clinical trials are completed, it will apply for production. After passing the review and approval of the State Food and Drug Administration and obtaining the approval documents for drug production, it can produce
products and go on sale. 6. Impact on Listed Companies and Risk Tips
The company's approval notice for drug clinical trials will not have a significant impact on the company's recent operating results. Due to the particularity of drug research and development, the pre-development of drugs and the long cycle and many links from development, clinical trials to production of products are easily affected by some uncertain factors. There are many uncertainties in the progress and results of clinical trials and the future product market competition situation. The company will be based on the progress of research and development in a timely manner to fulfill the obligations of information disclosure, so that the majority of investors pay attention to investment risks.
hereby announce
Zhejiang Jianfeng Group Co., Ltd. Board of Directors
January 6, 2001
More information
July 1 is the anniversary of the founding of the Communist Party of China. The party committee of the group organized the party members of the group headquarters and the heads of the grassroots party organizations to go to Jinggangshan, the red holy land, to retake the revolutionary road taken by the ancestors and review the history of revolutionary struggle.
2023
07-11
The Party Committee of the Group organized a thematic education seminar to study
On June 27, the Party Committee of the Group Company organized an education seminar on the theme of studying and implementing Xi Jinping's thoughts on socialism with Chinese characteristics in the new era. Jiang Xinwang, a professor and master tutor of Zhejiang Normal University, explained the deployment requirements of economic work and Xi Jinping's economic thoughts in the report of the 20th National Congress of the Communist Party of China with the theme of "accelerating the construction of a new development pattern and promoting high-quality development.
2023
07-11
Jianfeng Pharmaceutical rehired Academician Wang Guangji as Chief Scientist
On April 30, Jiang Xiaomeng, chairman of the group company and chairman of Jianfeng Pharmaceutical Company, on behalf of Jianfeng Pharmaceutical Company, issued a letter of appointment to Professor Wang Guangji, academician of the Chinese Academy of Engineering, and renewed him as the chief scientist of the pharmaceutical company.
2023
05-11
Jinhua Development Conference and Wucheng Development Conference
On April 30 and May 1, the third Jinhua Development Conference and the second Wucheng Development Conference opened successively. Jiang Xiaomeng, secretary of the party committee and chairman of the group company, won two major awards at the "Jinhua Development Outstanding Achievement Award" and "Wucheng Development Merit Award" at the two conferences, and participated in the Jinhua Life and Health Industry Summit roundtable and other activities.
2023
05-11
Daye Peak Cement Company, National "Green Factory"!
The Ministry of Industry and Information Technology recently announced the 2022 national green manufacturing list, Daye Peak Cement Company successfully ranked among the national "green factories. Green manufacturing is also known as environmentally conscious manufacturing, that is, in the manufacturing process, a modern manufacturing model that comprehensively considers environmental impact and resource benefits. Its purpose is to use technical means to optimize manufacturing procedures, minimize the impact on the environment (negative effect), and resource utilization The highest rate, and the coordination and optimization of economic and social benefits of enterprises, so as to achieve the purpose of resource conservation and sustainable development. In recent years, with the rapid development of social economy, the state attaches great importance to the construction of ecological civilization and ecological environment protection, and further promoting the construction of green manufacturing system has become an important means to promote high-quality development and maintain green water and green mountains forever. As an important part of the green manufacturing system, the Ministry of Industry and Information Technology has organized and carried out the creation of national-level green factories since 2017, and has conducted nationwide selection. It is an authoritative recognition for companies that meet the "green development" and aims to improve my country's green Manufacturing system, comprehensive implementation of green manufacturing, and help the industrial sector achieve the goal of carbon peak and carbon neutrality, it is an important way to promote the structural optimization of various industries, to get out of trouble and upgrade, and to improve quality and efficiency. Green factory refers to the realization of land intensive, raw materials harmless, clean production, waste resources, energy low-carbon factories. As the production unit of the manufacturing industry, the factory is the main body of the implementation of green manufacturing, which belongs to the core support unit of the green manufacturing system, focusing on the greening of the production process. Over the years, Daye Jianfeng has been adhering to the concept of green and low-carbon development, making every effort to build a garden-style factory. Through formulating plans and subdividing targets, it has clearly defined the total energy consumption and pollutant emission targets, and through carrying out school-enterprise cooperation to promote industry-university-research, it has actively implemented the strategy of "carbon peak and carbon neutrality", invested a huge amount of funds every year for technological transformation, and successively implemented technological transformation projects such as electric bags and low-nitrogen combustion upgrading, take the lead in the application of emission reduction technologies such as wet desulfurization and precise denitrification in the cement industry in Hubei Province, and continue to promote energy conservation, consumption reduction, and emission reduction. After the technical transformation, the company can save 3000 tons of standard coal every year, reduce the intensity of carbon dioxide emissions by 3.6, improve the level of energy-saving and green environmental protection management, and achieve the goal of creating a green factory. Being rated as a national-level green factory is not only a high affirmation and encouragement of Daye Peak's adherence to green, low-carbon and innovative development, but also an opportunity for Daye Peak to further promote green development. The person in charge of Daye Peak said that in accordance with national requirements, local industrial and information authorities should strengthen the connection between the units listed in the green manufacturing list and relevant industrial policies, give full play to the demonstration role of point to area, lead the green transformation of the manufacturing industry in the region, strengthen tracking guidance and dynamic management, and review the key indicators specified in the dynamic management table, Daye Peak will be in the future work, we will continue to further promote the management of environmental protection, energy conservation and emission reduction, give full play to the leading role of green factories in benchmarking, make low-carbon energy conservation, green environmental protection and reduce energy consumption the main keynote of enterprise development, and make continuous efforts to promote the high-quality development of enterprises and local economy. (Junin)
2023
04-03
"Cement Economy 50 People Forum" Jiang Xiaomeng Talk about the Future Development of Cement Industry
On March 14, the "Cement Economy 50 Forum" hosted by China Cement Network was held in Hangzhou, inviting 50 influential economic figures in the cement industry to discuss the future development of China's cement industry. Jiang Xiaomeng, chairman of the group company, was invited to attend the forum to discuss the development of the cement industry with his peers. The theme of this forum is "strengthening confidence, seeking breakthrough, and promoting development". It aims to point out the disadvantages of "mud", actively provide suggestions for the competent departments, enterprise transformation and upgrading, strategic and tactical decision-making in the difficult period of the cement industry, and provide new think tank opinions and methods to help form a new cement economic ecology. In the context of the sharp decline in demand, the cement industry is trapped inside and outside, how to revive the glory? How do cement companies survive and develop next? Around these two topics, the guests at the meeting had a heated discussion. Jiang Xiaomeng pointed out in his speech at the forum that the development of any enterprise is inseparable from the healthy development of the industry. Only when the industry is good can the enterprise be good, and the interests of the industry are greater than the interests of the enterprise. In addition, the competition of similar enterprises should seek a breakthrough from the differentiation, and it is unreasonable to blindly pursue low prices. Industry synergy, industry synergy, supply, demand, price, to find a common price line, on the basis of competition and cooperation, from the management services, cost control and other aspects to highlight the advantages of enterprises. The participants reached consensus on many issues after heated discussions. It is generally believed that 2022 is the most complex year in the cement industry in the past decade, affected by the multi-point spread of the epidemic, real estate downturn and other factors, the cement market demand is sluggish, the contradiction between supply and demand is prominent, prices are falling rapidly, business difficulties, the pace of steady growth of the industry is blocked. Entering 2023, under the macroeconomic situation of stabilizing the economy and promoting development, as well as various regions stepping up efforts to promote the construction of major projects, cement demand is expected to increase in 2023 compared with 2022, and the situation in the second half of the year will be better than that in the first half. However, under the expectation of restorative growth in demand, the cement industry is still facing uncertainties such as continued bottoming of real estate, high energy costs, and overcapacity. In this regard, we should resolutely maintain the normal order of the industry, make concerted efforts to help the industry get out of the predicament, and firmly implement staggered peak production. Through mergers and acquisitions, carbon quotas, energy efficiency indicators, environmental protection indicators, coal indicators, market competition and other means to further resolve the contradiction of overcapacity, optimize the industrial layout, and adhere to innovation-driven in digital, intelligent and green development, so as to promote and finally realize the high-quality development of the cement industry. (this newspaper reporter)
2023
03-21